Not available
Quote | BioLineRx Ltd. (NASDAQ:BLRX)
Last: | $0.6368 |
---|---|
Change Percent: | 2.53% |
Open: | $0.66 |
Close: | $0.6368 |
High: | $0.67999 |
Low: | $0.618 |
Volume: | 422,349 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | BioLineRx Ltd. (NASDAQ:BLRX)
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...
Message Board Posts | BioLineRx Ltd. (NASDAQ:BLRX)
Subject | By | Source | When |
---|---|---|---|
BioLineRx to Report First Quarter 2023 Results on | midastouch017 | investorshub | 05/17/2023 12:03:40 PM |
Philip Serlin: I would like to take a | midastouch017 | investorshub | 05/11/2023 5:17:14 PM |
1.6792+0.1692 (+11.2053%) | midastouch017 | investorshub | 05/11/2023 3:10:39 PM |
Lets go go go go... Up up and away we go. | midastouch017 | investorshub | 05/11/2023 2:03:17 PM |
Three out of four: Protlix also received marketing | midastouch017 | investorshub | 05/11/2023 12:48:56 PM |
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...
BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing t...